EL
ELUT.US Elutia Inc.
- Market cap
- USD 36.4M
- P/E
- -
- P/B
- 2.53x
- ROE
- -142.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ELUT.US undervalued?
Graham numberThe Graham number of Elutia Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Elutia Inc. fundamental analysis
No fundamental analysis for Elutia Inc. yet.
Elutia Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also o…
Full company profileElutia Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Elutia Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 39.0M | 42.9M | 42.7M | 47.4M | 23.8M | 24.7M | 24.4M | 12.3M | 8.90M |
| Gross Profit | 15.9M | 19.8M | 20.6M | 19.0M | 11.6M | 11.1M | 10.7M | 6.60M | 5.27M |
| Operating Income | -8.22M | -8.41M | -13.6M | -23.0M | -35.2M | -30.5M | -35.7M | -26.9M | -27.5M |
| EBITDA | -2.22M | -2.67M | -12.3M | -15.7M | -27.3M | -31.7M | -48.3M | -13.1M | -27.7M |
| Net Income | -11.6M | -11.9M | -21.8M | -24.8M | -32.9M | -37.7M | -53.9M | 53.4M | -21.9M |
| EPS | -1.08 | -1.12 | -2.13 | -2.38 | -2.38 | -2.07 | -1.86 | 1.13 | -0.46 |
| Balance Sheet | |||||||||
| Total Assets | 47.7M | 44.8M | 82.8M | 67.2M | 68.8M | 43.4M | 36.1M | 62.4M | 48.2M |
| Total Liabilities | 91.1M | 99.9M | 62.0M | 53.6M | 73.9M | 82.0M | 82.4M | 34.7M | 32.9M |
| Shareholders' Equity | -43.4M | -55.1M | 20.8M | 13.5M | -5.03M | -38.6M | -46.3M | 27.7M | 15.3M |
| Cash & Short-term Investments | 2.41M | 2.48M | 39.2M | 30.4M | 17.0M | 19.3M | 13.2M | 36.4M | 29.1M |
| Total Debt | 82.4M | 25.5M | 30.6M | 23.2M | 25.4M | 24.0M | 24.0M | 11.2M | 8.10M |
| Cash Flow | |||||||||
| Operating Cash Flow | -5.13M | -7.23M | -13.6M | -15.4M | -21.4M | -21.8M | -22.7M | -44.8M | -32.6M |
| Capital Expenditure | 190K | 577K | 640K | 369K | 540K | 346K | 654K | 1.88M | 789K |
| Free Cash Flow | -5.32M | -7.80M | -14.3M | -15.8M | -22.0M | -22.1M | -23.3M | -46.7M | -33.3M |
| Ratios | |||||||||
| ROE | - | - | -104.8% | -183.7% | - | - | - | 192.9% | -142.7% |
| ROA | -24.2% | -26.7% | -26.4% | -37.0% | -47.8% | -86.7% | -149.3% | 85.6% | -45.4% |
| Net Profit Margin | -29.6% | -27.8% | -51.1% | -52.4% | -137.9% | -152.2% | -221.3% | 434.2% | -245.6% |
| Debt to Equity | - | - | 1.47x | 1.72x | - | - | - | 0.40x | 0.53x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Elutia Inc. dividends
Elutia Inc. has not paid dividends in the last 8 fiscal years.
Who owns Elutia Inc.
- Insiders 3.57%
- Institutions 43.21%
- Public & others 53.22%
- Shares outstanding 44.4M
- Free float 29.7M
Top funds holding ELUT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 900K | 2.03% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 139K | 0.31% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 106K | 0.24% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 44.7K | 0.10% | 0.00% | Sep 2026 |
| Perkins Discovery | 37.5K | 0.08% | 0.00% | Mar 2026 |
| Fidelity Series Total Market Index | 36.7K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 9.30K | 0.02% | 0.00% | Aug 2026 |
| Vanguard U.S. Eq Idx £ Acc | 8.14K | 0.02% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 7.58K | 0.02% | 0.00% | Sep 2026 |
Top institutions holding ELUT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6.37M | 14.38% | +100.00% | Jun 2026 |
| AIGH Capital Management, LLC | 2.70M | 6.09% | -25.02% | Jun 2026 |
| Knollwood Investment Advisory LLC | 2.56M | 5.77% | 0.00% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 2.19M | 4.95% | -12.21% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.14M | 2.58% | +11.61% | Jun 2026 |
| Perkins Capital Management Inc | 694K | 1.57% | -8.30% | Jun 2026 |
| Geode Capital Management, LLC | 285K | 0.64% | -2.78% | Jun 2026 |
| CI Private Wealth LLC | 254K | 0.57% | +1.79% | Jun 2026 |
| Renaissance Technologies Corp | 202K | 0.46% | +143.99% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 172K | 0.39% | +44.49% | Jun 2026 |
| BlackRock Inc | 168K | 0.38% | +37.51% | Jun 2026 |
| Birchview Capital, LP | 165K | 0.37% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 124K | 0.28% | +10.17% | Jun 2026 |
| Rossmore Private Capital | 120K | 0.27% | 0.00% | Jun 2026 |
| GSA Capital Partners LLP | 89.4K | 0.20% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 52.6K | 0.12% | +37.89% | Jun 2026 |
| Jane Street Group LLC | 44.7K | 0.10% | -30.24% | Jun 2026 |
| Northern Trust Corp | 44.7K | 0.10% | +61.49% | Jun 2026 |
| Atom Investors LP | 44.2K | 0.10% | 0.00% | Jun 2026 |
| LRI Investments, LLC | 25.2K | 0.06% | 0.00% | Jun 2026 |
Elutia Inc. company profile
- Company name
- Elutia Inc.
- Ticker
- ELUT.US
- Exchange
- USA Stocks
- Listed since
- Sep 7, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 25
- Fiscal year end
- December
- Address
- 20 Firstfield Road, Gaithersburg, MD, United States, 20878
- Phone
- 240 247 1170
- Website
- elutia.com
About Elutia Inc.
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery. The company provides SimpliDerm, a human acellular dermal matrix used in soft tissue reconstruction. It also offers ProxiCor for cardiac tissue repair for use as an intracardiac patch for repairs, such as atrial and ventricular septal defects and suture-line buttressing, and pledgets, as well as for pericardial closure to reconstruct the pericardium after heart surgery. In addition, the company provides Tyke, a thinner pliable matrix for the repair of pericardial structures for neonates and infants; as an epicardial for damaged or repaired cardiac structures; and as a patch material for cardiac defects, as well as VasCure, a patch material to repair or reconstruct the peripheral vasculature. The company sells its products directly to hospitals and other healthcare facilities through independent sales agents. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Gaithersburg, Maryland.
Elutia Inc. management
8- Dr. C. Randal Mills Ph.D.Co-Founder, President, CEO & Director · born 1972
- Mr. Matthew B. FergusonChief Financial Officer · born 1968
- Dr. Michelle LeRoux Williams Ph.D.Chief Scientific Officer · born 1975
- Ms. Tamara GrossettHead of People
- Dr. Sonali Fonseca Ph.D.VP & Head of Emerging Businesses
- Mr. Dwayne MontgomeryHead of Cardiovascular · born 1968
- Mr. Peter J. LigottiChief Commercial Officer
- Mr. Jeffry D. HametSenior VP of Finance, Treasurer & Secretary